New York City, New York Feb 18, 2021 (Issuewire.com) - Avicanna (TSX: AVCN) (OTCQX: AVCNF) is a driving Biopharmaceutical Advancements of Plant-derived Cannabinoid-based Products throughout North and South America.
During the past four months, the Avicanna has experienced an incredibly successful launch with overwhelming positive support by the medical community including 300 prescribers and 20 clinics.
Avicanna sales have increased 100%+ month over month in all product categories. The early results show the product formulary key demographics are 55% women, 47% are 51-75 years of age and 90% of consumers are 30+ years old.
Avicanna will remain exclusive to Medical Cannabis by Shoppers for medical/prescription use and intends to increase its current commercial SKU’s from 4 to 10 in 2021.
Avicanna is a commercial-stage, diversified, and vertically-integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for global consumer, medical cannabis, and pharmaceutical market segments.
Avicanna also manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia.
Through these sustainable, economical, and industrial-scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients.
Not only has Avicanna launched and now placed its products into the $3billion dollar Canadian retail market through its partnership with Shoppers Drug Mart, seeing a sales increase 100%+ month over month in all product categories, but they are also seeing the revenue fruition from their endeavors:
• Four consecutive quarters of double-digit + increase in revenue and cost reductions
• Commercial stage and diversified revenue streams, across global markets including Canada, US, UK, and LATAM
• Agreement with Medical Cannabis by Shoppers, for the distribution of RHO Phyto products across Canada
• Propietary R&D, preclinical and clinical platforms including 3 years of IP development, team of 10+ scientists, and world-class clinical collaborations
• R&D headquarters at JLABS @ Toronto in MaRS Discovery District, inside the Johnson & Johnson Innovation Centre
• Proprietary cannabinoid product lines addressing consumer retail, medical cannabis and Rx markets, including Pura H&WTM and RHO PhytoTM
• Pharmaceutical pipeline of dermatology, neurology, oncology and pain management products
• World-class vertical integration,
cultivation, extraction, purification, production, and manufacturing (global GMP Certifications)
• Low cost and sustainable cultivation, with 480,000 sq ft in Santa Marta, Colombia
Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), is a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, that is now aggressively fueling revenue through the massive expansion and placement of it products through retail channels in early 2021 in Canada.
Media Contact
Management Affiliates cg@managementaffiliatesllc.com 805.521.6186
